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Introduction: Long-term outcomes remain unknown after stereo-
tactic body radiation therapy (SBRT). We observed a few patients
who developed disease progression late, at 5 years or more, after
SBRT. In this report, we describe the characteristics of those
patients with late recurrence after SBRT.
Methods: We retrospectively reviewed patients who underwent
SBRT for non-small cell lung cancer with histological confirmation
between January 1999 and December 2005 at our institution. During
this period, 48 Gy of SBRT in four fractions at the isocenter was
prescribed for all patients.
Results: In total, 66 patients were eligible. With a median follow-up
period of 35.9 months, the 5-year overall survival and disease-free
survival rates were 44.6% (95% confidence interval, 33.5–59.5%)
and 33.8% (95% confidence interval, 23.6–48.4%), respectively. Of
the patients, 16 survived without disease progression for 5 years or
more after SBRT. Of these, four patients developed late recurrence
at 76, 101, 108, and 109 months after SBRT. Three of the patients
were females with adenocarcinomas; the other was a male with
squamous cell carcinoma. The initial sites of recurrence were local
in two patients, distant in one, and simultaneously local and distant
in one. A total of two patients with local recurrence alone were still
alive at 138 months after SBRT.
Conclusions: The rate of late recurrence was not negligible in
long-term survivors after SBRT. Our experiences indicate that
long-term follow-up is needed after SBRT for non-small cell lung
cancer.
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Stereotactic body radiation therapy (SBRT) is a recentlydeveloped and innovative radiotherapeutic technique that has
been applied primarily to the lungs. SBRT is one of the more
important treatment options for early non-small cell lung cancer
(NSCLC), especially in inoperable or elderly patients.
Recently, initial outcomes have been reported from pro-
spective multi-institutional trials of SBRT for early-stage
NSCLC. The outcomes were satisfying and promising. In the
Radiation Therapy Oncology Group (RTOG) 0236 trial, a phase
II trial of SBRT for medically inoperable stage I/II NSCLC, the
3-year local control and overall survival rates were 98 and 56%,
respectively.1 In operable patients with stage IA NSCLC in the
Japan Clinical Oncology Group (JCOG) 0403 trial, those rates
were 86 and 76%, respectively.2
Long-term outcomes are still unknown for NSCLC
after SBRT. We observed a few patients who developed
disease progression late, at 5 years or more, after SBRT. In
this report, we describe our experience with and review the
characteristics of patients with late recurrence.
PATIENTS AND METHODS
We retrospectively reviewed patients who underwent
SBRT for NSCLC with histological confirmation between
January 1999 and December 2005 at our institution. In this
period, 48 Gy of SBRT in four fractions at the isocenter was
prescribed for all patients.
SBRT was performed as described previously.3,4 The
planning target volume was defined as the internal target
volume, which was delineated on slow-scan computer tomog-
raphy (CT), with a 5-mm margin for setup uncertainty.
Follow-up visits were every 2 to 3 months for 5 years after
SBRT and every 6 months thereafter. CT was performed every
2 to 4 months during the first year, every 6 months between 1
and 5 years after treatment, and annually thereafter. 18F-fluoro-
deoxyglucose-positron emission tomography (FDG-PET) was
not mandatory but indicated for patients suspected of recurrence.
RESULTS
In total, 66 patients were eligible. The median age was
76.5 (range, 67–86) years at the time of treatment. Of the 66
patients, 47 were males and 19 were females. According to
the classification with recursive partitioning analysis pro-
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posed in our previous report,5 34 patients were classified in
recursive partitioning analysis class I with a better prognosis;
the remaining 32 patients were in class II (Table 1).
At the time of analysis, the median follow-up period
was 35.9 (range, 4.2–138.2) months in the whole group and
60.0 (range, 6.9–138.2) months in the surviving patients. The
median survival time was estimated to be 47.5 months (95%
confidence interval [CI], 34.1–87.3 months). The 5-year
overall survival and disease-free survival rates were 44.6%
(95% CI, 33.5–59.5%) and 33.8% (95% CI, 23.6–48.4%),
respectively.
A total of 16 patients survived without disease progres-
sion for 5 years or more after SBRT. The characteristics of
these patients are shown in Table 1.
Among these 16 patients, four developed late recur-
rence at 76, 101, 108, and 109 months after SBRT. Table 2
summarizes the characteristics of this patient group, which
included three females with adenocarcinomas and one male
with squamous cell carcinoma. Surgery was contraindicated
because of intercurrent diseases in all four patients. The
initial site of recurrence was local in two patients, distant in
one, and simultaneously local and distant in one patient.
Local progression was diagnosed based on CT combined with
FDG-PET in three patients. After the recurrence, best sup-
portive care was chosen except for patient 3. Gefitinib had
been temporarily administered to patient 3; however, it was
stopped due to liver dysfunction. After the recurrence, two
patients (patients 1 and 2) died of lung cancer. To date, at 138
months after SBRT, the other two female patients are alive
with local disease (i.e., no evidence of metastasis) (Figure 1).
DISCUSSION
We previously investigated prognostic factors after
SBRT for stage I NSCLC and concluded that sex and tumor
diameter were the most significant factors.5 Based on these
results, we defined two prognostic classes: class I, consisting
of T1a patients and female patients, and class II, consisting of
male patients with T1b-2a tumors. Between the classes,
significant differences were observed in local recurrence,
disease progression, and overall survival after SBRT. The
class II patients tended to develop early recurrence compared
with the class I. In this study, 11 of 34 class I patients (32.4%)
survived without disease progression for 5 years, whereas
only five of 32 patients (15.6%) in the class II did. However,
these prognostic factors were validated only for recurrence or
death in the early period after treatment. To our best knowl-
edge, there was no article available on late recurrence after
SBRT for NSCLC. This study focused on late recurrence.
Recurrence at 5 years or later after surgery for stage I
NSCLC has been reported by several authors. Thomas and
Rubinstein6 of the Lung Cancer Study Group reported late
lung cancer recurrence in 22 of 308 patients (7.1%) who were
clinically free of cancer 5 years or more after surgery for
T1N0M0 NSCLC. Pasini et al.7 reported that late relapse,
including metachronous lung cancer, developed in 15% of
patients who were disease-free at 5 years after surgery for
T1–2N0M0 NSCLC. Maeda et al.8 recently reported that late
recurrence was observed in 4.8% of patients who were free
from recurrence for 5 years after complete resection of stage
IA NSCLC (locoregional recurrence in 2.1% and distant
metastasis in 2.8%). From these reports, the rate of late
recurrence after surgery is less than 10%, except for meta-
chronous lung cancer. In our study, late recurrence was
observed in four of 16 long-term survivors (25%) without
disease progression for 5 years after SBRT. This seemed to
be more frequent than the surgical series. When SBRT is
applied to younger and operable patients, late recurrence
would be expected to become an issue, similar to the patients
presented here.
This study has some limitations. First, the number of
long-term survivors was small. SBRT is often performed in
frail patients who cannot tolerate surgery, and some of these
patients die of intercurrent diseases rather than lung cancer.
Indeed, 14 of the 39 patients who died in our cohort had no
evidence of lung cancer recurrence. Long-term follow-up for
lung cancer control would be limited in these patients. Sec-
ond, this study was based on a retrospective review; thus, it
was prone to selection bias. Long-term outcomes are awaited
after prospective SBRT trials, such as RTOG 0236 and JCOG
0403. Third, our SBRT regimen of 48 Gy in four fractions at
the isocenter, which is the same as the JCOG 0403, was lower
than the doses in the United States (60 Gy in three fractions
at the planning target volume periphery) as the RTOG 0236
used. A difference was observed in 3-year local control rate
TABLE 1. Characteristics of All Patients Reviewed in this Study
and of Patients Free from Recurrence at 5 yr After SBRT
All Patients
(n  66)
Patients Free from
Recurrence at 5 yr
(n  16)
Age at SBRT (yr)
Median (range) 76.5 (67–86) 77 (68–86)
Sex
Male 47 11
Female 19 5
PS
0 39 10
1 23 6
2 4 0
Histology
Adenocarcinoma 32 10
Squamous cell carcinoma 29 6
Others 5 0
T-stagea
T1a 22 8
T1b 25 5
T2a 19 3
RPA classb
Class I 34 11
Class II 32 5
SBRT, stereotactic body radiation therapy; PS, performance status; RPA, recursive
partitioning analysis.
a T-stage was retrospectively evaluated according to the 7th edition of TNM
classification of Malignant Tumors.
b RPA class I was defined as female or T1a patients and class II as male patients
with T1b-2a tumors.5
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between the JCOG 0403 and the RTOG 0236 (86 versus
98%). The possibility might exist that such a lower prescrip-
tion dose causes late recurrence of local tumor. Another
limitation was that local progression was not histologically
confirmed but was diagnosed based on imaging. There are
some difficulties in the radiological diagnosis of local recur-
rence after SBRT. A mass-like consolidation prevents us
from evaluating local tumors on CT after SBRT. In our
previous report, enlargement of the consolidation at 12
months or more after SBRT indicated local recurrence.9 Our
study of FDG-PET revealed that moderate to intense FDG
uptake observed soon after SBRT did not always indicate a
residual tumor.10 From these experiences, we suspect local
progression when a local consolidation enlarges continuously
on CT, especially at 1 year or more after treatment. A
well-defined and intense FDG uptake will support the CT
findings in the late period after SBRT. Although the local
tumor was properly diagnosed as a malignancy based on
imaging, we could not determine whether the local tumor was
due to regrowth of the residual cancer or a secondary cancer.
FIGURE 1. Computer tomography (CT) (A) and fluorodeoxyglucose-positron emission tomography (FDG-PET) (B) images for
patient 4. A, CT images: A 21-mm tumor was located in the right upper lobe in an 81-year-old woman. Stereotactic body ra-
diation therapy (SBRT) was performed for the tumor, with 48 Gy in four fractions. Radiation pneumonitis was observed at 8
months after SBRT. It shrank into a mass-like consolidation by 16 months after SBRT and persisted at a stable size for 95
months. The consolidation showed regrowth at 109 months. After that, the tumor gradually enlarged. B, FDG-PET images:
Before SBRT, the tumor had a localized uptake with a maximum standardized uptake value (SUVmax) of 3.6. At 48 months after
SBRT, uptake by the tumor was ill defined, with an SUVmax of 2.1 (arrowhead). At 115 months, the FDG uptake of the tumor be-
came intense and well defined, with an SUVmax of 6.6.
TABLE 2. Characteristics of the Four Patients Who Developed Recurrence at 5 yr or Later After SBRT
Patient
Age at
SBRT (yr) Sex PS Histology T-Stage
Time of
Recurrence (mo) Site of Recurrence
Last
Follow-Up (mo) Status
1 78 F 0 Ad T1a 76 Distant (brain) 79 Dead
2 76 M 1 Sq T1b 101 Local and distant (lung and liver) 112 Dead
3 80 F 0 Ad T1b 108 Local 138 Alive
4 81 F 0 Ad T1b 109 Local 138 Alive
SBRT, stereotactic body radiation therapy; PS, performance status; Ad, adenocarcinoma; Sq, squamous cell carcinoma.
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These issues will be addressed in prospective trials of SBRT
for operable patients with NSCLC (e.g., RTOG 0618).
In conclusion, the rate of late recurrence was not
negligible in long-term survivors after SBRT. Our experi-
ences indicate that long-term follow-up after SBRT for
NSCLC is needed.
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